new and novel agents for dlbcl: bispecifics, car-t, and more
Published 1 year ago • 123 plays • Length 7:58Download video MP4
Download video MP3
Similar videos
-
2:03
the next generation of novel agents in development for aggressive b-cell lymphoma
-
7:08
unmet needs and therapeutic targets for diffuse large b-cell lymphoma and follicular lymphoma
-
4:10
the use of adcs & bispecific antibodies before and after car-t therapy in third-line dlbcl
-
7:56
regulatory considerations and challenges surrounding new and emerging therapies for lymphoma
-
7:05
new and emerging therapies for follicular lymphoma, including treatment challenges
-
1:30
bispecific antibodies for r/r aggressive b-cell lymphomas
-
29:00
dlbcl in 2023: top docs discuss the latest in diffuse large b-cell lymphoma | treatments & research
-
4:58
overview of the toxicities associated with bispecific agents in multiple myeloma
-
4:58
novel immunotherapies transforming r/r myeloma treatment: bispecifics, car-t cells & more
-
8:38
how should treatment be sequenced for dlbcl, follicular lymphoma?
-
1:28
how the standard of care for dlbcl is changing with the introduction of novel agents
-
2:02
bispecific antibodies for b-cell lymphoma treatment | oncotarget
-
39:28
new horizons in r/r follicular lymphoma: risk stratification & practicalities of car t-cell therapy
-
1:09
the changing role of allosct in dlbcl in the era of novel agents
-
1:24:16
perspectives on novel antibody platforms in dlbcl
-
16:32
new antibodies and antibody-drug conjugates for b-cell lymphoma
-
12:15
car-t vs bispecific antibodies for lymphoma
-
6:31
what are the emerging targets for lymphoma?